China-NZ CAR-T Deal Valued at USD 130m

Summary

Wellington Zhaotai Therapies Limited (WZTL), the holding platform of China's Zhaotai, has signed a CAR-T cell therapy technology sublicence agreement with New Zealand's BioOra in Auckland, with a total contract value of USD 130 million. It is the first time Guangdong province has commercially licensed an independently developed tumour immunotherapy cell therapy product to a developed country. WZTL is 86.5 percent owned by China's Zhaotai and 13.5 percent by MBL, an entity under New Zealand's Malaghan Institute of Medical Research, and is the core delivery platform for nearly a decade of China-New Zealand biomedical research collaboration.

Under the agreement, the CAR-T therapy products will be jointly advanced through subsequent clinical development and commercialisation in agreed international markets outside Greater China and India. Tang Zhaoyang, chairman of China's Zhaotai and WZTL, said the USD 130 million deal is the result of nearly a decade of sustained investment by research teams from both countries. In 2016, China's Zhaotai began technical cooperation with the Malaghan Institute; in 2017, the two sides jointly established WZTL; in 2019, they signed a deepened cooperation agreement during the entrepreneurs' conference of the second Belt and Road Forum for International Cooperation, and launched New Zealand's first nationwide CAR-T clinical trial the same year; in 2023, at the Guangzhou event marking the 50th anniversary of China-New Zealand diplomatic relations, the project was highlighted by then New Zealand Ambassador to China, Grahame Morton.

Previously, in 2022, China's Zhaotai commercially licensed a CAR-T innovative drug for lymphoma to India's Dr Reddy's Laboratories; in 2024, China Customs approved its CAR-T cell products for entry into Hong Kong hospitals. Tang said the signing is a key step for independently innovative technology to go global through the China-New Zealand cooperation network, and that the company will continue to work with BioOra and more industry chain partners to advance subsequent clinical development and commercialisation of the therapy in agreed international markets, while creating more high-end medical industry jobs and commercial returns for New Zealand.

Commentary

The USD 130 million CAR-T technology sublicence agreement between China's Zhaotai and New Zealand's BioOra marks an important milestone in China-New Zealand biomedical cooperation, moving from joint research and development to commercialisation. As a frontier field in tumour immunotherapy, CAR-T therapies are expected to exceed USD 10 billion globally by 2027, but high costs and manufacturing complexity remain commercialisation bottlenecks. In this deal, the Malaghan Institute's participation through holding platform WZTL reflects New Zealand's strengths in clinical research and regulation, while China's Zhaotai provides independently owned intellectual property technology, creating complementarity.

For NZ SMEs, the cooperation could bring opportunities to participate in the cell therapy supply chain, such as cold chain logistics, biomanufacturing equipment and clinical trial services. New Zealand's biotechnology industry is small but high in research quality, and the deal is expected to attract more international capital to the local innovation ecosystem. At the same time, Chinese pharmaceutical companies have accelerated licence-out deals in recent years, with total upfront payments for outbound licensing exceeding USD 40 billion in 2023, showing growing international recognition of China's innovative drugs.

However, commercialisation of CAR-T therapies still faces challenges such as production standardisation and payment systems, and New Zealand companies need to assess their ability to enter specific segments. From a regional perspective, Guangdong, as a major Chinese biomedical hub, may offer New Zealand a new path for technology introduction and joint development through its companies' overseas expansion model.

Keywords: CAR-T cell therapy, technology sublicence, China's Zhaotai, New Zealand's BioOra, USD 130 million, China-New Zealand cooperation, Wellington Zhaotai Therapies, Malaghan Institute of Medical Research, Tang Zhaoyang, commercialisation licence

Summary in Chinese | 摘要

中国昭泰旗下持股平台惠灵顿昭泰治疗有限公司（WZTL）与新西兰BioOra在奥克兰正式签署CAR-T细胞疗法技术再许可协议，合同总金额达1.3亿美元。这是广东省首次将自主研发的肿瘤免疫细胞治疗产品成功向发达国家进行商业化授权。WZTL由中国昭泰持股86.5%，新西兰马拉格汉医学研究中心旗下主体MBL持股13.5%，是中新双方近十年生物医药科研合作的核心落地平台。

根据协议，相关CAR-T疗法产品将在大中华区和印度以外的约定国际市场，由合作双方共同推进后续临床开发与商业化落地。中国昭泰、WZTL董事长汤朝阳表示，本次1.3亿美元交易是中新双方科研团队近十年持续投入的结果。2016年，中国昭泰启动与新西兰马拉格汉医学研究中心的技术合作；2017年双方共同成立WZTL；2019年在第二届“一带一路”国际合作高峰论坛企业家大会期间签署深化合作协议，同年启动新西兰全国首个CAR-T临床试验；2023年在中新建交50周年庆祝活动广州场中，该项目由时任新西兰驻华大使毛瑞重点推介。

此前，2022年中国昭泰将针对淋巴瘤的CAR-T创新药物商业授权给印度Dr Reddy’s Laboratories；2024年中国海关批准其CAR-T细胞产品进入香港医院。汤朝阳称，这次签约是自主创新技术通过中新合作网络走向全球的关键一步，未来将与BioOra及更多产业链伙伴持续协作，推动该疗法在约定国际市场完成后续临床开发和商业化落地，并为新西兰本地创造更多高端医疗产业岗位、商业收益。

Commentary in Chinese | 评论

中国昭泰与新西兰BioOra达成的1.3亿美元CAR-T技术再许可协议，是中新生物医药合作从联合研发迈向商业化的重要节点。CAR-T疗法作为肿瘤免疫治疗的前沿领域，全球市场预计2027年将超百亿美元，但高昂成本和制造复杂性仍是商业化瓶颈。此次交易中，新西兰马拉格汉医学研究中心通过持股平台WZTL参与，体现了新西兰在临床研究和监管方面的优势，而中国昭泰提供自主知识产权技术，形成互补。

对NZ中小企业而言，这一合作可能带来参与细胞治疗供应链的机会，例如冷链物流、生物制造设备、临床试验服务等。新西兰生物技术产业规模虽小但研发质量高，此次交易有望吸引更多国际资本关注本地创新生态。同时，中国药企近年加速License-out交易，2023年对外授权首付款总额已超400亿美元，显示中国创新药国际认可度提升。

然而，CAR-T疗法的商业化仍面临生产标准化、支付体系等挑战，新西兰企业需评估自身在细分环节的切入能力。从区域视角看，广东作为中国生物医药重镇，其企业出海模式或为新西兰提供技术引进与联合开发的新路径。

关键词: CAR-T细胞疗法, 技术再许可, 中国昭泰, 新西兰BioOra, 1.3亿美元, 中新合作, 惠灵顿昭泰治疗, 马拉格汉医学研究中心, 汤朝阳, 商业化授权

Source: Economic and Commercial Office of the Ministry of Commerce at the Chinese Consulate-General in Auckland